PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505486-92-00

Acronym

PRODIGE 86

Enrollment

170

Registered

2023-09-29

Start date

2024-02-09

Completion date

Unknown

Last updated

2025-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small bowel adenocarcinoma

Brief summary

Progression at 8 months

Detailed description

Survival, Pregression-free survival

Interventions

DRUGOXALIPLATIN

DRUGFLUOROURACIL

DRUGIRINOTECAN HYDROCHLORIDE TRIHYDRATE

DRUGCALCIUM LEVOFOLINATE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression at 8 months	—

Secondary

Measure	Time frame
Survival, Pregression-free survival	—

Countries

France, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026